Novel missense variants in the RNF213 gene from a European family with Moyamoya disease

Andrey N. Gagunashvili1, Louise Ocaña1, Daniel Kelberman1, Pinki Munot2, Chiara Bacchelli1, Philip L. Beales1 and Vijeya Ganesan2,3

Abstract
In this report, we present a European family with six individuals affected with Moyamoya disease (MMD). We detected two novel missense variants in the Moyamoya susceptibility gene RNF213, c.12553A>G (p.(Lys4185Glu)) and c.12562G>A (p.(Ala4188Thr)). Cosegregation of the variants with MMD, as well as a previous report of a variant affecting the same amino acid residue in unrelated MMD patients, supports the role of RNF213 in the pathogenesis of MMD.

Moyamoya (MM) is a rare cerebrovascular disorder that is characterized by a high rate of stroke and frequent recurrence. When MM is associated with a recognized genetic or acquired condition, it is termed MM syndrome (MMS). The majority of cases appear to be idiopathic in origin and are termed MM disease (MMD). Linkage studies have identified a number of loci in reports of cases, albeit with incomplete penetrance, suggesting a role for genetic factors in the etiology of MMD. Elucidation of the genes involved has been hampered by several complicating factors, including clinical and radiological phenotypic heterogeneity, incomplete penetrance and variable onset of the disease. The inheritance pattern in the majority of cases is unclear. The use of whole-exome sequencing has allowed for the identification of a number of rare variants in genes linked to rare Mendelian forms, particularly when associated with a broader spectrum of disease in patients with MMS. However, in idiopathic cases of MMD, variations in the RNF213 gene have been identified as conferring susceptibility to MMD. In particular, a founder variant c.14429G>A (p.(Arg4810Lys) (dbSNP accession rs112735431)) has been observed in 80% of Japanese and East Asian MMD patients, compared to 2% in the general population. The diversity of susceptibility variants in MMD patients of European ancestry remains underrepresented.

In this report, we analyzed a white European family from the UK with six relatives affected with MMD over three generations (Fig. 1a) (for a detailed description of the clinical presentation, see Supplementary Text S1). In an attempt to find a genetic cause of MMD in this family, two affected and three unaffected members of the family (denoted with a plus sign in Fig. 1a) underwent whole-exome sequencing to an average coverage of 104.6× (range of 98.4–108.5×) such that, on average, 96.2% of the exome capture target regions was covered by at least 20× (for a detailed description of the methods see Supplementary Text S2). We focused our analysis on coding and splice region variants (single nucleotide variants and indels) that are not present or rare (allele frequency <0.5%) in public databases of human genetic variation: ExAC/gnomAD, 1000 Genomes Project and NHLBI ESP.
Fig. 1 Novel missense variants in the RNF213 gene from a European family with MMD. 

a Pedigree of the family. The genotypes of the two RNF213 variants are shown below each family member for which a DNA sample was available, where red refers to the status of the missense variant c.12553A>G (p.(Lys4185Glu)), and blue refers to the status of the missense variant c.12562G>A (p.(Ala4188Thr)) (reference allele/alternate allele). Filled symbols denote affected individuals, unfilled symbols denote unaffected individuals, and slashed lines denote deceased. Five individuals who were whole-exome sequenced are denoted with a plus sign. P, proband. The genotypes of other family members were obtained with Sanger sequencing.

b The domain structure of the RNF213 protein based on14 and variants previously reported in East Asian and European MMD patients1,2,5,11–20 (shown above and below the protein, respectively). The variants reported for both populations are underlined, and the ones identified in this study are shown in blue. Two distinct regions with different missense constraints identified by Samocha and coworkers6 are shown below the protein.

c Conservation of amino acid residues affected by the c.12553A>G (p.(Lys4185Glu)) and c.12562G>A (p.(Ala4188Thr)) variants. AAA+, ATPases associated with various cellular activity domains; RING, RING-finger domain.

H. sapiens
P. troglodytes
C. lupus
B. taurus
M. musculus
R. norvegicus
G. gallus
D. rerio
X. tropicalis

Gagunashvili et al. Human Genome Variation (2019) 6:35
Page 2 of 5

Official journal of the Japan Society of Human Genetics
Analysis of filtered genetic variants was performed assuming a dominant mode of inheritance. X-linkage could not be excluded due to the absence of any male-to-male transmission within the pedigree. However, there is at least one instance of nonpenetrance in the family as individual II:8, although clinically unaffected, is an obligate carrier of the variant(s) that he passed onto his affected daughter (III:9). Consequently, individual II:8 was classified as “affected” for the purpose of the genetic analysis (for a detailed description of the variant analysis, see Supplementary Text S3). The observation of incomplete penetrance is consistent with other reports of MMD inheritance.1,3,4

No potential candidate variants were identified that were consistent with an X-linked dominant mode of inheritance (Supplementary Fig. S2). Analysis of the autosomes identified 20 candidate variants, 16 of which were predicted to be deleterious to protein function (missense and frameshift variants) (Supplementary Fig. S2, Supplementary Table S1). Of these sixteen candidates, two missense variants, c.12553A>G (p.(Lys4185Glu)) and c.12562G>A (p.(Ala4188Thr)) (Supplementary Table S1), were identified in the RNF213 gene, which has previously been reported as a major susceptibility gene for MMD.1,2 No other candidates were identified in our analysis that could explain the disease in the affected family members.

The parental aunt (II:1) and uncle (II:5) of the proband are both obligate carriers of these variants, both having affected children (III:1, III:2 and III:7) (Supplementary Fig. S3 and S4, Supplementary Table S2). These individuals are clinically asymptomatic and are currently undergoing clinical evaluation. Brain imaging studies have not been undertaken to date.

The variants identified are currently private to the family and have not been previously documented or reported in public databases (Table 1). Both variants cosegregate with MMD in multiple affected family members and obligate carriers (Supplementary Fig. S5). The p.(Lys4185Glu) is a conservative amino acid substitution that occurs at a position that is conserved across members and obligate carriers (Supplementary Fig. S5). Interestingly, both East Asian and European MMD patients show very little overlap in European MMD-associated variants can be explained by a spread of spontaneously arisen mutations.

According to the gnomAD database, RNF213 has been identified as a major susceptibility gene for MMD, mostly in cases of East Asian ancestry. Interestingly, both East Asian and European MMD patients show very little overlap in RNF213 variants associated with the disease (Fig. 1b). Apart from the founder variant c.14429G>A (p. (Arg4810Lys))2, the differences between East Asian and European MMD-associated variants can be explained by a spread of spontaneously arisen mutations.

Table 1 Summary of the RNF213 variants found in the European family with MMD

| Variant 1 | Variant 2 |
|----------|----------|
| Position (GRCh38) | chr17:80,372,536 | chr17:80,372,545 |
| Variant consequences | Missense Missense |
| Variant genotype | Heterozygous Heterozygous |
| cDNA change | c.12553A>G (NM_001256071.2) | c.12562G>A (NM_001256071.2) |
| Protein change | p.(Lys4185Glu) (NP_001243000.2) | p.(Ala4188Thr) (NP_001243000.2) |
| Transcript length | 21,062 bp | 21,062 bp |
| Protein length | 5207 aa | 5207 aa |
| Exon/exons in transcript | 48/68 | 48/68 |
| Allele frequency in public databases: | | |
| ExAC/gnomAD | 0 | 0 |
| 1000 Genomes | 0 | 0 |
| NHLBI ESP | 0 | 0 |
| Presence in dbSNP | Not present | Not present |
| Variant classification | Likely pathogenic | Uncertain significance |
| ClinVar accession | SCV000839587 | SCV000839588 |

benign, suggesting that this variant may have a limited impact on the resultant protein (Supplementary Table S3). Genetic studies of familial MMD are complicated by considerable heterogeneity, incomplete penetrance of the condition and variable onset of the disease. RNF213 has been identified as a major susceptibility gene for MMD, mostly in cases of East Asian ancestry. Interestingly, both East Asian and European MMD patients show very little overlap in RNF213 variants associated with the disease (Fig. 1b). Apart from the founder variant c.14429G>A (p. (Arg4810Lys))2, the differences between East Asian and European MMD-associated variants can be explained by a spread of spontaneously arisen mutations.
haploinsufficiency are known to cause severe disease. This observation can explain the reduced penetrance of MMD in families carrying rare RNF213 variants and suggests that other factors, including genetic background, are required to trigger the development of the disease.

In this case, we identified two novel missense variants in the RNF213 gene in a European family with MMD. The occurrence of two private variants on the same allele 7 bp apart (Supporting Fig. S3) suggests the possibility that they have arisen as a result of a single mutational event. It has been shown previously that such clustered, multi-nucleotide mutations can be introduced by the normal activity of the more error-prone components of the DNA repair pathway, such as polymerase zeta. The presence of an indel or a larger structural variant at the locus was not evident from the mapped sequencing reads (Supplementary Fig. S3).

The variants are situated in the C-terminal region of the RNF213 protein, where the majority of MMD-associated variants have been reported (Fig. 1b). This region harbors a domain for a RING-finger E3 ligase, which is involved in the ubiquitination of substrates targeted for either proteasomal degradation or signal transduction. Interestingly, this part of RNF213 represents one of the two distinct segments (1–3725 and 3726–5207 amino acids) with different missense constraints identified by Samocha and coworkers (Fig. 1b). This suggests that missense variants in this region may have different deleterious effects on the protein function compared to the variants in the first segment of RNF213. Applying the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP) guidelines, we interpreted the p.(Lys4185Glu) variant in the RNF213 gene as likely pathogenic for MMD, acting in a dominant manner. The p.(Ala4188Thr) variant was interpreted as a variant of uncertain significance with respect to MMD due to conflicting/insufficient evidence (for a detailed description of the variant interpretation see Supplementary Text S4). We could not exclude the possibility of a synergistic effect of having both of these variants in cis to cause the phenotype. It will be interesting whether other unrelated MMD patients who carry only one variant will be found. The study of such cases may not only confirm the role of the variants in the pathogenesis of MMD but may also reveal some phenotypic differences between the carriers. The multiple reported occurrence of individuals exhibiting reduced penetrance for a particular disease can complicate genetic studies and make it difficult to draw firm conclusions regarding the association of a particular gene with disease pathogenesis. To overcome this, the reporting of novel variants associated with diseases such as MMD is important to greatly facilitate variant interpretation in the future. Multiple recurrences of the same variant or variants within the same gene (particularly affecting the same amino acid residue) in unrelated patients provide increasing supportive evidence for disease association. Our findings support and add more evidence to the importance of alteration of the C-terminal region of RNF213, including the RING-finger domain, in the pathogenesis of MMD. This study also adds important weight to a growing body of evidence that variation in the RNF213 gene also has an important role in disease susceptibility in European populations.

HGV database
The relevant data from this Data Report are hosted at the Human Genome Variation Database at https://www.gtexportal.org/hgvs/hgv.2588, https://doi.org/10.6084/m9.figshare.hgv.2591.

Acknowledgements
This research is funded by the NIHR GOSH BRC. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. The authors would like to thank Heidi Rehm for the help with variant interpretation.

Author details
1. GOSgene, Genetics and Genomic Medicine, UCL Great Ormond Street Institute of Child Health, London, UK. 2. Neurology Department, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK. 3. Clinical Neurosciences, UCL Great Ormond Street Institute of Child Health, London, UK

Data Availability
The variants identified in this study were deposited in the ClinVar database under accession numbers SCV001395957 and SCV001395988. Additional data can be found in the Supplementary Information online.

Ethics approval and consent to participate
This study was approved by an independent research ethics committee: London and Bloomsbury REC Ref. 12/LO1293.

Conflict of interest
The authors declare that they have no conflict of interest.

Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information is available for this paper at https://doi.org/10.1038/s41439-019-0066-6.

Received: 27 March 2019 Revised: 6 June 2019 Accepted: 21 June 2019

References
1. Kamada, F. et al. A genome-wide association study identifies RNF213 as the first Moyamoya disease gene. J. Hum. Genet. 56, 34–40 (2011).
2. Liu, W. et al. Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS ONE 6, e22542 (2011).
3. Mineharu, Y. et al. Inheritance pattern of familial Moyamoya disease: autosomal dominant mode and genomic imprinting. J. Neurol. Neurosurg. Psychiatry 77, 1025–1029 (2006).
4. Mineharu, Y. et al. Autosomal dominant moyamoya disease maps to chromosome 17q25.3. *Neurology* **70**, 2357–2363 (2008).
5. Smith, K. R. et al. Identification of a novel RNF213 variant in a family with heterogeneous intracerebral vasculopathy. *Int. J. Stroke* **9**, E26–E27 (2014).
6. Samocha, K. E. et al. Regional missense constraint improves variant deleteriousness prediction. bioRxiv 148353 (2017).
7. Besenbacher, S. et al. Multi-nucleotide de novo mutations in humans. *PloS Genet.* **12**, e1006315 (2016).
8. Harris, K. & Nielsen, R. Error-prone polymerase activity causes multinucleotide mutations in humans. *Genome Res.* **24**, 1445–1454 (2014).
9. Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet. Med.* **17**, 405–424 (2015).
10. Gelb, B. D. et al. ClinGen’s RASopathy Expert Panel consensus methods for variant interpretation. *Genet. Med.* **20**, 1334–1345 (2018).
11. Cecchi, A. C. et al. RNF213 rare variants in an ethnically diverse population with Moyamoya disease. *Stroke* **45**, 3200–3207 (2014).
12. Kobayashi, H. et al. RNF213 rare variants in Slovakian and Czech moyamoya disease patients. *PloS ONE* **11**, e0164759 (2016).
13. Guery, S. et al. Rare RNF213 variants in the C-terminal region encompassing the RING-finger domain are associated with moyamoya angioopathy in Caucasians. *Eur. J. Hum. Genet.* **25**, 995–1003 (2017).
14. Monto, D. et al. Moyamoya disease-associated protein mysterin/RNF213 is a novel AAA+ ATPase, which dynamically changes its oligomeric state. *Sci. Rep.* **4**, 4442 (2014).
15. Wu, Z. et al. Molecular analysis of RNF213 gene for moyamoya disease in the Chinese Han population. *PloS ONE* **7**, e48179 (2012).
16. Miyatake, S. et al. Homozygous c.14576G>A variant of RNF213 predicts early-onset and severe form of moyamoya disease. *Neurology* **78**, 803–810 (2012).
17. Lee, M.-J. et al. Mutation genotypes of RNF213 gene from moyamoya patients in Taiwan. *J. Neurol. Sci.* **353**, 161–165 (2015).
18. Harel, T. et al. Atypical presentation of moyamoya disease in an infant with a de novo RNF213 variant. *Am. J. Med. Genet. Part A* **167**, 2742–2747 (2015).
19. Shoemaker, L. D. et al. Disease variant landscape of a large multiethnic population of moyamoya patients by exome sequencing. *G3: Genes, Genomes, Genet.* **6**, 41–49 (2016).
20. Akagawa, H. et al. Novel and recurrent RNF213 variants in Japanese pediatric patients with moyamoya disease. *Hum. Genome Var.* **5**, 170860 (2018).